European Respiratory Society

Peters emphasized how the new findings reinforce treatment strategies for chronic rhinosinusitis with nasal polyps.

Bhatt discussed the latest data from a post-hoc analysis of the BOREAS and NOTUS trials.

Hanania discussed the rationale and findings of the BOREAS and NOTUS studies.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

Novel insights into the risk-benefit profile of nintedanib in children and adolescents with fibrosing interstitial lung disease (ILD) were provided by late-breaking data presented at ERS 2022 regarding the InPedILD clinical trial.

Late-breaking data presented at ERS Congress 2022 show that inhaler sensors and mobile health (mHealth) applications combined with pharmacist counseling improved treatment adherence for patients with uncontrolled asthma.

These data support web-based self-management for individuals with COPD with an objective, clinically relevant, short-term increase in physical activity levels compared to usual care.

“From this study it makes sense that the (icenticaftor) 300mg dose has a benefit-risk profile to further study the clinical benefits,” Dr. Frits Franssen, lead investigator, said at ERS Congress 2022.

As with previous studies, the investigators found that the biologic aided in reducing severe exacerbations and improving lung function in patients with evidence type 2 inflammation.

Investigators believe the current climate crisis can lead to an increased risk of COPD exacerbations and mortality rates, both of which have been noted in prior research.

HRV-induced cytokine responses were reduced in patients with severe asthma.

Pulmonary conditions like asthma could often lead to the development of chronic cough.

Despite not being able to attend conferences live, there are some advantages to a virtual conference.

The molecular mechanisms of steroid resistance suggest the P13K/Akt signaling pathway and the MAPK signaling pathway are involved.

New cohort analysis shows an over-reliance on therapy designed as an add-on for asthma control.

Asthma patients have not had higher rates of negative outcomes from COVID-19 than other individuals.

The biologic drug is set to be used as a combination therapy for asthma.

In a study presented at ERS, researchers IOS could be used for assessment level of asthma control in both adult and pediatric patients.

New data shows nearly 40% of chronic lung disease patients from a Portuguese hospital died within 5 years of initiating respiratory rehabilitation.

Patients saw improvement in symptom perception, activity limitation, emotional function, and environmental stimuli.

It has been approximately 60 years since a new treatment for coughs has come on the market.

Obese-related asthma is considered one of the more severe asthma phenotypes.

Data shows certain personality traits are linked to a COPD patient's likelihood of active or sedentary behaviors.

The added indication makes the GSK single inhaler triple therapy the first of its kind approved for both asthma and COPD in the US.

Telemedicine has become an important tool during the COVID-19 pandemic.

Problems using inhalers correctly is an ongoing issue for both pediatric and adult patients.

New ERS findings show patients hospitalized for COVID-19 bettered from timelier, personalized rehabilitation plans.

A $25 genetic test could inform physicians on optimal controller therapy for children and adolescents with asthma.

In a new study presented at ERS 2020, Dr. Mark Levy discusses how a digital inhaler reduces the amount of people who use their inhaler incorrectly.

The risk of cardiovascular hospitalizations was associated with increasing PM10 at lag 0.